this study reports on the occurence of JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.
No takes yet. Share an insight, caveat, or question.
Pieri et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: